Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77 (market cap $3.10B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is more actively traded (1,668,577 versus 1,095,314). Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 17 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FLRN | TVTX | |
|---|---|---|
Market Cap | $3.10B | $4.88B |
Volume | 1,095,314 | 1,668,577 |
Sector | Fixed Income | Health |
52-Week High | $30.86 | $67.52 |
52-Week Low | $30.65 | $26.79 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN, the SPDR Bloomberg Investment Grade Floating Rate ETF, trades at $30.77 with no recent price change. Technical indicators signal a bearish trend, while recent news highlights its appeal as a floating-rate bond ETF amid rising interest rates. The ETF has announced several small dividends for 2026, but key financial ratios like P/E and P/B are unavailable.
The outlook for FLRN is mixed; its near-zero duration and floating-rate structure offer protection against rate hikes, attracting institutional interest. However, significant financial sector exposure and bearish technical signals pose risks. Investors should weigh the defensive characteristics against market volatility and sector-specific headwinds.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
